Hikma Pharmaceuticals PLC Hikma Pharmaceuticals PLC the Company 81 Notes to the Company financial statements 1.
Significant accounting policies The separate financial statements of the Company are presented as required by the Companies Act 1985.
As permitted by that Act, the separate financial statements have been prepared in accordance with International Financial Reporting Standards and UK law.
The financial statements have been prepared on the historical cost basis.
The principal accounting policies adopted are the same as those set out in Note 2 to the consolidated financial statements with the addition of the policy as noted below.
Investments in subsidiaries are stated at cost less, where appropriate, provisions for impairment.
Investment in Subsidiaries Investment in subsidiaries represents 100% share in Hikma Pharma Limited Jersey, 100% of Hikma Holdings, 100% of Hikma Limited and 52.5% of Al Jazeera Pharmaceutical Industries: the cost method is used to account for these investments.
On 10 November 2006 the Company subscribed 9,038 Ordinary Shares of 1 each in the share capital of Hikma Holdings UK Limited for an aggregate amount of $591,865,487, $65,487 was paid up in cash and the remaining of $591,800,000 was left outstanding in the intercompany account.
Financial assets Cash and cash equivalents These comprise cash held by the Company and short-term bank deposits with an original maturity of three months or less.
The carrying amount of these assets approximates their fair value.
Financial liabilities Other payables The Directors consider that the carrying amount of other payables approximates to their fair value.
Staff costs Hikma Pharmaceuticals PLC currently has four employees: total compensation paid to them amounted to $923,000 2005: $117,000 of which salaries and wages compromise an amount of $492,000 2005: $73,000 the remaining balance of $367,000 2005: $44,000 represent social security and other benefits.
Share options The details of the share compensation scheme are provided in Note 35 to the Group financial statements.
The number of options granted to the employees of the Company including Directors was 2,600,000 2005: 2,560,000 and the total amount of the compensation expenses charged to income statement is $196,400 2005: $172,000.
Share capital 2006 2005 $000s $000s Authorised: 500,000,000 Ordinary Shares of 10 pence each 88,700 88,700 49,998 non-voting, redeemable Preference Shares of 1 each 90 The Company redeemed the Preference Shares at par on 9 February 2006.
2006 2005 Number 000s $000s Number 000s $000s Issued and fully paid included in shareholders equity: At start of period 166,798 29,457 142,400 25,269 Issued during the year 1,366 255 24,398 4,188 At 31 December 168,164 29,712 166,798 29,457 Hikma Pharmaceuticals PLC Hikma Pharmaceuticals PLC the Company 82 8.
Share premium Share premium $000s Balance at 8 September 2005 Premium arising on issue of Equity Shares 828,253 Expenses on issue of Equity Shares 10,810 Balance at 31 December 2005 817,443 Premium arising on issue of Equity Shares 1,357 Balance at 31 December 2006 818,800 9.
Retained earnings Included in the retained earnings an amount of $196,400 2005: $172,000 represents the current year charge of share option expenses.
Contingent liabilities At 31 December 2006, the Company has agreed to guarantee the payment of the $591,800,000 from Hikma Holdings UK Ltd to Hikma Acquisitions UK Ltd.
The guarantee relates to loan notes issued to Hikma Acquisitions UK Limited by Hikma Holdings UK Ltd as consideration for the transfer of the entire issued share capital in Hikma UK Limited to Hikma Holdings UK Ltd as part of the Hikma Group reorganisation.
Subsequent events In January 2007, the Group announced the acquisition of Ribosepharm GmbH for consideration of $45 million.
The book value of assets acquired was $0.6 million.
The Group is currently in the process of determining the fair value adjustments and hence the goodwill and intangibles arising on the acquisition.
Due to the timing of this transaction, it has been impractical to calculate and disclose the amounts arising.
